Here’s a roundup of recent clinical trial and scientific study news:
- pSivida touts latest diabetic macular edema study results
pSivida Corp. (NSDQ:PSDV), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema (DME), announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences Inc. (ALIM). Alimera previously presented the month 24, top-line results from the now completed FAME Study. The FAME Study consisted of two 3-year, Phase 3 pivotal clinical trials (Trial A and Trial B) to assess the safety and efficacy of ILUVIEN in the treatment of DME.
- Metamark Genetics announces landmark prostate cancer study published in Nature
Metamark Genetics Inc., a privately-held oncology molecular diagnostics company, announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature. The study describes the identification of a key tumor suppressor of prostate cancer progression in mice and humans, as well as reveals four markers that are predictive of biochemical recurrence and lethal metastasis in human prostate cancer. The study, entitled “Smad4-dependent barrier constrains prostate cancer growth and metastatic progression,” was conducted by Metamark scientific co-founders, Drs. Lynda Chin and Ronald DePinho.
- NIH researchers extend use of gene therapy to treat a soft tissue tumor
Results of an intermediate stage clinical trial of several dozen people provides evidence that a method that has worked for treating patients with metastatic melanoma can also work for patients with metastatic synovial cell sarcoma, one of the most common soft tissue tumors in adolescents and young adults. This study is the first to use genetically modified immune cells, in a technique known as adoptive therapy, to cause cancer regression in patients with a solid cancer as opposed to melanoma. This approach represents a method for obtaining immune cells from any cancer patient and converting them into ones that can recognize cancer cells expressing the target antigen, NY-ESO-1, according to researchers at the National Cancer Institute. The study appeared in the Jan. 31, 2011, issue of the Journal of Clinical Oncology.
- Cappella Medical Devices announces first enrolled patients in Italian Sideguard study
Cappella Medical Devices announces initiation of the multi-center Italian Sideguard open label clinical study. The Principal Investigator (PI) of the study, Dr. Giuseppe Massimo Sangiorgi at the Policlinico di Modena – University of Modena and Reggio Emilia, in Modena, Italy stated, “The side branch ostium anatomy requires a unique technology solution to effectively manage and optimize treatment. The shape and elastic properties of the nitinol Sideguard stent provide constant outward radial force on the lumen and ostium providing support and protection of the side branch over time and hopefully reducing neointimal proliferation at the ostium of the side branch in the long term follow-up. The Sideguard system is an easy-to-use solution for treating bifurcation disease and we are looking forward to being part of this study.”
- Registered nurses seeking jobs will need more advanced degrees
As the nursing job market tightens, candidates for registered nurse positions are increasingly in need of more education to separate themselves from the pack to get hired. And the jobs that registered nurses end up landing are increasingly likely to come outside of hospitals. Those are two key findings from the latest biannual study of nursing supply and demand released by the Greater Cincinnati Health Council, a group of hospitals and health systems from the region. The study is based on data gathered from 13 Cincinnati-area hospitals and 10 nursing schools, according to MedCity News.